[Netilmicin in a single daily dose for treatment of systemic infections]. / Netilmicina in dose singola giornaliera nel trattamento di infezioni sistemiche.

The Authors report the results obtained in 35 patients of either sex suffering from various systemic infections and treated with netilmicin. Netilmicin has been intramuscularly administered in once daily dose of 4.5 mg/kg (mean daily dose 294.3 mg) for a mean duration of 17.8 days. The clinical resolution of the infections has been achieved in 97.1% (34 patients) of the study population; only one patient showed failure. Thirty-three of the 35 baseline causative pathogens have been eradicated. The local and systemic tolerability was good. The serum pharmacokinetics showed bactericidal levels of netilmicin and no serum accumulation.

[Clinico-epidemiologic study on 1258 cases of viral hepatitis admitted to Piedmont hospitals 1977-1979]. / Indagine clinico-epidemiologica su 1258 casi di epatite virale, ricoverati in Piemonte negli anni 1977-79.

A clinical and epidemiological assessment of 1258 hospital patients in Piedmont in 1977-1979 showed that, at present, the frequency of hepatitis A and B can be regarded as virtually the same, that males are more frequently affected, that AVH A is more frequent in early life, whereas AVH B is significantly more common later, that urban areas are more frequently stricken than rural areas, that AVH A is more common in persons living in groups, whereas AVH B is more frequent among pensioners and the unemployed (the latter being primarily drug-addicts). Patients with AVH A, and hence a minor hepatitic involvement, had shorter hospital stays, while the immune response in both types of hepatitis is characterized by a more frequent increase in gamma-globulins, coupled with arise in IgM levels.

[Clinical picture of Reye's syndrome in an adult]. / Quadro clinico di sindrome di Reye in un adulto.

The case of a young man of 20 who, after aspecific prodromic symptomatology of viral type, presented a clinical picture characterised by encephalitis and hepatitis classifiable in Reye's syndrome is reported. Bioenzymatic data and therapeutic outlook are discussed.